Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature

Hum Pathol. 2016 Dec:58:72-77. doi: 10.1016/j.humpath.2016.07.025. Epub 2016 Aug 18.

Abstract

Follicular lymphoma with MYC and BCL2 translocations, so-called double-hit follicular lymphoma (DH-FL), is rare. Here, we report the clinicopathological features of 7 cases of DH-FL. All neoplasms had a follicular pattern (1 partially diffuse). Five cases were predominantly low grade, 4 of which had focal (≤20%) grade 3A areas, and 2 cases were of grade 3. All cases were positive for pan-B-cell antigens, CD10, and BCL6; 6 cases were positive for BCL2. Ki-67 was less than or equal to 50% in 6 cases and 90% in 1 grade 3 case. Three patients presented with stage IV disease and 3 had a Follicular Lymphoma International Prognostic Index score of greater than 2. Six patients received immunochemotherapy, and 1 is still under induction therapy with rituximab, ibrutinib, and lenalidomide. Four achieved complete remission and two had a partial response with persistent or refractory disease. The median follow-up time was 25 months (range, 8.5-53.7 months). Two patients treated with standard regimen for follicular lymphoma had relapsed or refractory disease, and 1 died from complications of allogeneic stem cell transplant administered for relapse. In contrast, all 4 patients treated with more intensive regimen for double-hit lymphoma achieved complete remission. In summary, despite predominantly low-grade histology, cases of DH-FL in this study were aggressive and responded better to more intensive than standard treatment regimens, suggesting DH-FL is part of the spectrum of double-hit high-grade lymphoma.

Keywords: B-cell; BCL2; Double-hit; Follicular lymphoma; MYC.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics*
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Immunotherapy / methods
  • In Situ Hybridization, Fluorescence
  • Ki-67 Antigen / analysis
  • Lymphoma, Follicular / chemistry
  • Lymphoma, Follicular / genetics*
  • Lymphoma, Follicular / pathology
  • Lymphoma, Follicular / therapy
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Phenotype
  • Proto-Oncogene Proteins c-bcl-2 / genetics*
  • Proto-Oncogene Proteins c-myc / genetics*
  • Recurrence
  • Remission Induction
  • Stem Cell Transplantation
  • Time Factors
  • Translocation, Genetic*
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • BCL2 protein, human
  • Biomarkers, Tumor
  • Ki-67 Antigen
  • MYC protein, human
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-myc